DealsMay 12, 2026, 08:32 AM
20/20 BioLabs Licenses Patented AI Algorithm for Prostate Cancer Detection
AI Summary
20/20 BioLabs, Inc. announced an exclusive, worldwide licensing agreement with the University of South Carolina to commercialize a patented algorithm. This technology analyzes changes in PSA levels over time to identify rapidly growing prostate tumors, enabling earlier detection even before standard PSA thresholds are met. The algorithm will be integrated into 20/20 BioLabs' OneTest for Cancer platform and offered to other clinical laboratories via SaaS licenses, supporting the company's mission to make early cancer detection more accessible. The company also anticipates joint research to develop similar algorithms for other cancer markers like CA 125 and CA 19.9.
Key Highlights
- 20/20 BioLabs entered an exclusive, worldwide licensing agreement with the University of South Carolina.
- The agreement is for a patented algorithm to identify aggressive prostate tumors earlier.
- The algorithm analyzes changes in prostate-specific antigen (PSA) levels over time.
- It enables detection even before PSA levels cross standard thresholds (typically 4.0 ng/mL).
- The algorithm will be incorporated into 20/20 BioLabs' OneTest for Cancer platform.
- It will also be available to other clinical laboratories worldwide under software-as-a-service licenses.
- Joint research is anticipated to develop similar algorithms for ovarian and pancreatic cancers.
Price Impact
More from AIDX